Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 802

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 802
---
 ​ |
| Net cash provided by financing activities                                                                                   | ​ | ​ | ​                       | ​ |   38,151 | ​ | ​ | ​ | ​    | ​ |     311 | ​ | ​ | ​ | ​    | ​ |   46,608 | ​ | ​ |
| Net (decrease) increase in cash, cash equivalents and restricted cash                                                       | ​ | ​ | ​                       | ​ |  -10,466 | ​ | ​ | ​ | ​    | ​ |  50,288 | ​ | ​ | ​ | ​    | ​ |  -18,230 | ​ | ​ |
| Cash, cash equivalents and restricted cash at beginning of period                                                           | ​ | ​ | ​                       | ​ |   64,149 | ​ | ​ | ​ | ​    | ​ |  13,861 | ​ | ​ | ​ | ​    | ​ |   32,091 | ​ | ​ |
| Cash, cash equivalents and restricted cash at end of period                                                                 | ​ | ​ | ​                       | $ |   53,683 | ​ | ​ | ​ | ​    | $ |  64,149 | ​ | ​ | ​ | ​    | $ |   13,861 | ​ | ​ |
| Noncash investing and financing activities                                                                                  | ​ | ​ | ​                       | ​ |        ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |        ​ | ​ | ​ |
| Accrual for leasehold improvements                                                                                          | ​ | ​ | ​                       | $ |      778 | ​ | ​ | ​ | ​    | $ |       — | ​ | ​ | ​ | ​    | $ |        — | ​ | ​ |

See Notes to Consolidated Financial Statements. F-40

TABLE OF CONTENTS

#### CARA THERAPEUTICS, INC.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
<div align='center'>**(amounts in thousands, except share and per share data)**</div>

### 1. Business
Cara Therapeutics, Inc., or the Company, is a development-stage biopharmaceutical corporation formed on July 2, 2004. The Company is leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s primary activities to date have been organizing and staffing the Company, developing its lead product